News and Trends 21 Jun 2017 British Biotech Tops up its Cancer Pipeline with New TCR Therapy Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […] June 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Novartis Gains Access to Celyad’s allogenic CAR-T cell patents Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […] May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2017 UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and Kite have been in a tight race to bring the first CAR-T therapy to market: Novartis has staked out acute lymphoblastic leukemia (ALL) while Kite has gone for DLBCL. With this “tacit endorsement,” Novartis is encroaching on […] April 19, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2017 Taking Cell Therapy one Step Further with this Boost Reagent Cell therapy is revolutionizing medicine, here’s how the latest technology can help overcome the major challenges stopping it from taking over the market. Offering unprecedented possibilities to treat some of the most challenging diseases, cell therapy is stealing the show in the biotech space. Strimvelis, the first hematopoietic stem cell (HSC) gene therapy is already […] April 12, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 16 Mar 2017 “In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality” David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […] March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2017 UK Immunotherapy Biotech raises Massive Funding in Series C The UK biotech Cell Medica picked up a massive €69M (£60M) in its recent Series C funding round to advance its cancer immunotherapy programs. Cell Medica is a clinical stage company developing cell-based therapies to treat cancer. With the aim of advancing the clinical development of its immunotherapies, the company was able to raise an impressive […] March 16, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Novartis Relies on Biotech to keep up its Solid Financial Performance Novartis has announced excellent results for 2016. Could its strong focus on biotech be the key to the big pharma’s success? Novartis just released its 2016 financial report, boasting €45.2B ($48.5B) in net sales and its therapeutic antibody for psoriasis, Cosentyx (secukinumab), becoming a blockbuster. The Swiss pharma is suffering competition from generics, but it expects […] January 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2016 The 8 Biggest Biotech Medical Fails of 2016 in Europe Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […] December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2016 The 10 Biggest Clinical Success Stories of 2016 in European Biotech What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […] December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 These are our 10 Most Read Biotech Articles of 2016 From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2 years, Labiotech.eu is now the leading biotech media in Europe, with over 50k monthly readers. To celebrate the end of another amazing year, we wanted […] December 20, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2016 Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis Amcure and TILT Biotherapeutics announced yesterday new financing rounds supporting the development of unique strategies to cure cancer metastasis. Amcure, in Germany, is fighting highly metastatic forms of cancer by targeting angiogenesis. The company just closed a Series B round with a total of €6M from already existing investors. With the funds, Amcure plans to accelerate […] December 16, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email